Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

doi:10.1038/s41591-018-0115-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Nature medicine - 1 Aug 2018

Quek Lynn, David Muriel D, Kennedy Alison, Metzner Marlen, Amatangelo Michael, Shih Alan, Stoilova Bilyana, Quivoron Cyril, Heiblig Maël, Willekens Christophe, Saada Véronique, Alsafadi Samar, Vijayabaskar M S, Peniket Andy, Bernard Oliver A, Agresta Sam, Yen Katharine, MacBeth Kyle, Stein Eytan, Vassiliou George S, Levine Ross, De Botton Stephane, Thakurta Anjan, Penard-Lacronique Virginie, Vyas Paresh

Abstract excerpt

Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-molecule inhibitor of mutant IDH2, produces a clinical response in 40% of treated patients with relapsed/refractory AML by promoting leukemic cell differentiation. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clone Cells

Share to Hematopoiesis

Share to Immunophenotyping

Share to Isocitrate Dehydrogenase

Share to Neoplasm Recurrence, Local

Share to Neoplastic Stem Cells

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 30013198
DOI: 10.1038/s41591-018-0115-6
PMCID: PMC6925974

Genes

IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.PMID 30013198Read ↗

Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.Semantic proximity Read ↗

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.Semantic proximity Read ↗

Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell GenomicsSemantic proximity Read ↗

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Semantic proximity Read ↗

Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.Semantic proximity Read ↗

IDH1- and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation.Semantic proximity Read ↗

Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.Semantic proximity Read ↗

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.Semantic proximity Read ↗

Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML.Semantic proximity Read ↗

The Leukemic IDH1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPC): Experimental Evidences and a Review of the LiteratureSemantic proximity Read ↗

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.